IsoPet® is now commercially available as part of a company-sponsored program to gain experience on the use of the
product and to share the results of this therapy with the veterinary community. Interested pet owners will have this completed form sent to Vivos, Inc CEO | President Dr. Mike Korenko.
Vista Veterinary Hospital will review the information and provide their recommendation
regarding applicability of IsoPet® therapy.
Important information regarding IsoPet®:
IsoPet® is designed to deliver a high dose of therapeutic radiation at the point of administration with no significant radiation extending beyond the treatment zone. IsoPet® is therefore
most appropriate for treating localized cancers, especially solid tumors with well-defined boundaries or margins.
IsoPet® is particularly attractive for treating tumors that would be difficult to remove surgically (non-resectable) but could be reached with a needle for
injecting the product.
IsoPet is not effective against distributed cancers, such as lymphomas, or advanced metastatic disease where the cancer has spread significantly beyond the tumor
site. IsoPet can only be expected to effectively treat the primary tumor.
At this time, IsoPet® is not recommended (is contra-indicated) for treating mast cell tumors due to the potential for systemic shock to the animal due to rapid
release of mast cells. Vivos, Inc. is exploring the possibility of a clinical study focused on this cancer type which would define the characteristics of mast cell tumors which could safely be
treated with IsoPet®.
You will be participating in a developmental therapy. The therapy has demonstrated limited, but positive results. The data from the tests will be made available to Vivos Inc. and other
clinics and could be included in published paper or conferences. Since it is developmental the pet owner recognizes there are risks.
IsoPET® therapy price is competitive with the cost of external beam radiation therapy.